Source: Annual Congress 2003 - Advances in our understanding of corticosteroids in the treatment of asthma
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Sheffer, M. Silverman, A. Woolcock, P. Diaz Amor, B. Lindmark, F. Radner (Boston, United States Of America; Leicester, United Kingdom; Sydney, Australia; Santiago, Chile; Lund, Sweden). Long-term safety data with once-daily budesonide in mild asthma: results from the START study. Eur Respir J 2003; 22: Suppl. 45, 338

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019 The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Effectiveness of early intervention with budesonide in mild persistent asthma — 5-year data from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Intermittent tiotropium in early childhood wheezing? Preliminary safety results of a pilot study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012